MEDIROM Healthcare Technologies reported a net loss of ¥588.4 million for H1 2024, widening from ¥355.1 million in H1 2023. Revenues increased 10.3% YoY to ¥3.48 billion, driven by growth in directly-operated salons. Operating loss expanded to ¥636.7 million from ¥379.0 million last year.The company continued expansion efforts, establishing MEDIROM Rehab Solutions to acquire a rehabilitation business for ¥20.9 million. It also entered agreements to acquire 70% of Japan Gene Medicine for ¥2 billion and formed capital alliances through its MOTHER Labs subsidiary, raising over ¥260 million from investors.MEDIROM faced liquidity challenges, with negative cash flows and an accumulated deficit as of June 30. To address this, the company refinanced debt, issued convertible bonds, and is pursuing additional capital raises, including a potential follow-on offering.

MEDIROM Healthcare Technologies reported a net loss of ¥588.4 million for H1 2024, widening from ¥355.1 million in H1 2023. Revenues increased 10.3% YoY to ¥3.48 billion, driven by growth in directly-operated salons. Operating loss expanded to ¥636.7 million from ¥379.0 million last year.The company continued expansion efforts, establishing MEDIROM Rehab Solutions to acquire a rehabilitation business for ¥20.9 million. It also entered agreements to acquire 70% of Japan Gene Medicine for ¥2 billion and formed capital alliances through its MOTHER Labs subsidiary, raising over ¥260 million from investors.MEDIROM faced liquidity challenges, with negative cash flows and an accumulated deficit as of June 30. To address this, the company refinanced debt, issued convertible bonds, and is pursuing additional capital raises, including a potential follow-on offering.